April marked the seventh month in a row that plaintiffs’ attorney advertisers spent over $3 million on ads seeking claims related to Risperdal, an antipsychotic drug by Janssen Pharmaceuticals, a unit of Johnson & Johnson.
The drug has been among the top two drugs or medical devices targeted in mass tort ads since October 2013.
Nearly 6,000 Risperdal mass tort ads ran in April. Over 85% of ad spending was devoted to ads aired on national cable and broadcast networks. The law firms of Pulaski & Middleman and Meyer Blair spent more on Risperdal ads than all other law firms combined.
In early November, Johnson & Johnson agreed to pay more than $2.2 billion in criminal and civil fines to settle accusations that is improperly promoted Risperdal to older adults, children and people with disabilities.
According to court records, Janssen has reached settlements in some 80 Risperdal suits in Philadelphia. Trials in a new set of cases are expected to begin in July.
The drug has been among the top two drugs or medical devices targeted in mass tort ads since October 2013.
Nearly 6,000 Risperdal mass tort ads ran in April. Over 85% of ad spending was devoted to ads aired on national cable and broadcast networks. The law firms of Pulaski & Middleman and Meyer Blair spent more on Risperdal ads than all other law firms combined.
In early November, Johnson & Johnson agreed to pay more than $2.2 billion in criminal and civil fines to settle accusations that is improperly promoted Risperdal to older adults, children and people with disabilities.
According to court records, Janssen has reached settlements in some 80 Risperdal suits in Philadelphia. Trials in a new set of cases are expected to begin in July.
RSS Feed
